| Trial ID: | L6313 |
| Source ID: | NCT04867707
|
| Associated Drug: |
Zanamivir
|
| Title: |
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
|
| Acronym: |
NAED
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Zanamivir
|
| Outcome Measures: |
Primary: Change in glycocalyx integrity, Measure of glycocalyx integrity via Glycocheck. Glycocalyx integrity measures will be performed non-invasively., 0 and 5 days | Secondary: Change in Vascular function, Flow mediated dilation (FMD) in arm. Brachial artery FMD measures will be performed non-invasively via Ultrasound., 0 and 5 days
|
| Sponsor/Collaborators: |
Sponsor: University of Missouri-Columbia
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-07-14
|
| Completion Date: |
2024-10-18
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-31
|
| Locations: |
University of Missouri, School of Medicine Clinical Research Center, Columbia, Missouri, 65212, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04867707
|
